FGFR3 and neoplasm: For invasive tumours (pT2-4), the two most common groups were also tumours wild-type for both FGFR3 and TP53 (88/207; 42.5% of cases) or wild-type for FGFR3 and mutated for TP53 (95/207; 45.9% of cases).